High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling

Background and Objective:Bupleurum falcatum (BF) extract, a natural product with anti-inflammatory properties, has been traditionally used to treat menopausal symptoms, but its role in osteoporosis, another serious health concern of menopausal women, remains unknown. Here we investigated whether and...

Full description

Bibliographic Details
Main Authors: Mijung Yeom, Eun-Young Kim, Jae-Hyun Kim, Hyuk-Sang Jung, Youngjoo Sohn
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2018.01314/full
_version_ 1818354048327221248
author Mijung Yeom
Eun-Young Kim
Jae-Hyun Kim
Hyuk-Sang Jung
Youngjoo Sohn
author_facet Mijung Yeom
Eun-Young Kim
Jae-Hyun Kim
Hyuk-Sang Jung
Youngjoo Sohn
author_sort Mijung Yeom
collection DOAJ
description Background and Objective:Bupleurum falcatum (BF) extract, a natural product with anti-inflammatory properties, has been traditionally used to treat menopausal symptoms, but its role in osteoporosis, another serious health concern of menopausal women, remains unknown. Here we investigated whether and how BF prevents estrogen deficiency-induced bone loss using both in vitro and in vivo models.Methods: Female Sprague-Dawley rats were ovariectomized (OVX) and subjected to oral BF treatment daily for 8 weeks. Additionally, pre-osteoclastic RAW 264.7 cells were employed to evaluate the effects of BF and its underlying mechanism on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast formation in vitro.Results: A high dose of BF partially prevented ovariectomy (OVX)-induced bone loss and reduced the levels of tartrate-resistant acid phosphatase (TRAP) in serum and osteoclast numbers in femurs of OVX rats. Furthermore, BF clearly inhibited RANKL-induced osteoclast differentiation and bone resorption activity in RAW 264.7 cells. BF also inhibited the osteoclastogenic transcription factors c-Fos and nuclear factor of activated T cells c1 (NFATc1) and, consequently, downregulated the expression of osteoclast marker genes. Moreover, BF upregulated interferon-β (IFN-β)/inducible nitric oxide synthase (iNOS)/nitric oxide (NO) signaling, even though it had no impact on mitogen-activated protein kinases (MAPK) or NF-κB. The inhibition of osteoclast formation by BF was abrogated by iNOS-specific inhibitors. Consistent with cellular studies, BF upregulated iNOS protein expression in femurs from OVX rats.Conclusion: Taken together, our results indicate that BF partially prevented estrogen deficiency-induced bone loss with anti-osteoclastogenic activity potentially due to enhanced iNOS/NO signaling.
first_indexed 2024-12-13T19:19:14Z
format Article
id doaj.art-d4530d04d637433abd9d1f70105a51d3
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-13T19:19:14Z
publishDate 2018-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-d4530d04d637433abd9d1f70105a51d32022-12-21T23:34:12ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-11-01910.3389/fphar.2018.01314416142High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO SignalingMijung Yeom0Eun-Young Kim1Jae-Hyun Kim2Hyuk-Sang Jung3Youngjoo Sohn4Acupuncture and Meridian Science Research Center, College of Korean Medicine, Kyung Hee University, Seoul, South KoreaDepartment of Anatomy, College of Korean Medicine, Kyung Hee University, Seoul, South KoreaDepartment of Anatomy, College of Korean Medicine, Kyung Hee University, Seoul, South KoreaDepartment of Anatomy, College of Korean Medicine, Kyung Hee University, Seoul, South KoreaDepartment of Anatomy, College of Korean Medicine, Kyung Hee University, Seoul, South KoreaBackground and Objective:Bupleurum falcatum (BF) extract, a natural product with anti-inflammatory properties, has been traditionally used to treat menopausal symptoms, but its role in osteoporosis, another serious health concern of menopausal women, remains unknown. Here we investigated whether and how BF prevents estrogen deficiency-induced bone loss using both in vitro and in vivo models.Methods: Female Sprague-Dawley rats were ovariectomized (OVX) and subjected to oral BF treatment daily for 8 weeks. Additionally, pre-osteoclastic RAW 264.7 cells were employed to evaluate the effects of BF and its underlying mechanism on receptor activator of nuclear factor kappa-B ligand (RANKL)-induced osteoclast formation in vitro.Results: A high dose of BF partially prevented ovariectomy (OVX)-induced bone loss and reduced the levels of tartrate-resistant acid phosphatase (TRAP) in serum and osteoclast numbers in femurs of OVX rats. Furthermore, BF clearly inhibited RANKL-induced osteoclast differentiation and bone resorption activity in RAW 264.7 cells. BF also inhibited the osteoclastogenic transcription factors c-Fos and nuclear factor of activated T cells c1 (NFATc1) and, consequently, downregulated the expression of osteoclast marker genes. Moreover, BF upregulated interferon-β (IFN-β)/inducible nitric oxide synthase (iNOS)/nitric oxide (NO) signaling, even though it had no impact on mitogen-activated protein kinases (MAPK) or NF-κB. The inhibition of osteoclast formation by BF was abrogated by iNOS-specific inhibitors. Consistent with cellular studies, BF upregulated iNOS protein expression in femurs from OVX rats.Conclusion: Taken together, our results indicate that BF partially prevented estrogen deficiency-induced bone loss with anti-osteoclastogenic activity potentially due to enhanced iNOS/NO signaling.https://www.frontiersin.org/article/10.3389/fphar.2018.01314/fullBupleurum falcatumpostmenopausal osteoporosisbone resorptionosteoclastsovariectomized rats
spellingShingle Mijung Yeom
Eun-Young Kim
Jae-Hyun Kim
Hyuk-Sang Jung
Youngjoo Sohn
High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling
Frontiers in Pharmacology
Bupleurum falcatum
postmenopausal osteoporosis
bone resorption
osteoclasts
ovariectomized rats
title High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling
title_full High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling
title_fullStr High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling
title_full_unstemmed High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling
title_short High Doses of Bupleurum falcatum Partially Prevents Estrogen Deficiency-Induced Bone Loss With Anti-osteoclastogenic Activity Due to Enhanced iNOS/NO Signaling
title_sort high doses of bupleurum falcatum partially prevents estrogen deficiency induced bone loss with anti osteoclastogenic activity due to enhanced inos no signaling
topic Bupleurum falcatum
postmenopausal osteoporosis
bone resorption
osteoclasts
ovariectomized rats
url https://www.frontiersin.org/article/10.3389/fphar.2018.01314/full
work_keys_str_mv AT mijungyeom highdosesofbupleurumfalcatumpartiallypreventsestrogendeficiencyinducedbonelosswithantiosteoclastogenicactivityduetoenhancedinosnosignaling
AT eunyoungkim highdosesofbupleurumfalcatumpartiallypreventsestrogendeficiencyinducedbonelosswithantiosteoclastogenicactivityduetoenhancedinosnosignaling
AT jaehyunkim highdosesofbupleurumfalcatumpartiallypreventsestrogendeficiencyinducedbonelosswithantiosteoclastogenicactivityduetoenhancedinosnosignaling
AT hyuksangjung highdosesofbupleurumfalcatumpartiallypreventsestrogendeficiencyinducedbonelosswithantiosteoclastogenicactivityduetoenhancedinosnosignaling
AT youngjoosohn highdosesofbupleurumfalcatumpartiallypreventsestrogendeficiencyinducedbonelosswithantiosteoclastogenicactivityduetoenhancedinosnosignaling